BREAST CANCER LINKAGE CONSORTIUM
Publications in peer reviewed journals


Consortium papers - updated until 17-05-2002

1993

  • Easton, D., Bishop, D., Ford, D., Crockford, G., and the Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am. J. Hum. Genet. 52: 678-701, 1993. (View Abstract)

1994

  • Ford, D., Easton, D., Bishop, D., Narod, S., Goldgar, D., and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692-695, 1994. (View Abstract)

1995

  • Cornelis, R., Neuhausen, S.L., Johansson, O., Arason, A., Kelsell, D., Ponder, B.A.J., Tonin, P., Hamann, U., Lindblom, A., Lalle, P., Longy, M., Olàh, E., Scherneck, S., Bignon, Y., Sobol, H., Chang-Claude, J., Larsson, C., Spurr, N., Borg, Å., Barkardottir, R.B., Narod, S., Devilee, P., and the Breast Cancer Linkage Consortium. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCA1-linked families. Genes Chrom. Cancer 13: 203-210, 1995. (View Abstract)
  • Børresen, A.-L., Andersen, T.I., Eyfjörd, J., Cornelis, R.S., Thorlacius, S., Borg, Å., Johansson, U., Theillet, C., Scherneck, S., Hartman, S., Cornelisse, C.J., Hovig, E., and Devilee, P. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zincbinding domains. Genes Chrom. Cancer 14: 71-75, 1995. (View Abstract)
  • Easton, D., Ford, D., Bishop, D., and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am. J. Hum. Genet. 56: 265-271, 1995. (View Abstract)
  • Narod, S., Ford, D., Devilee, P., Barkardottir, R., Lynch, H., Smith, S., Ponder, B., Weber, B., Garber, J., Birch, J., Cornelis, R., Kelsell, D., Spurr, N., Smyth, E., Haites, N., Sobol, H., Bignon, Y., Chang-Claude, J., Hamann, U., Lindblom, A., Borg, A., Piver, M., Gallion, H., Struewing, J., Whittemore, A., Tonin, P., Goldgar, D., Easton, D., and the Breast Cancer Linkage Consortium. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am. J. Hum. Genet. 56: 254-264, 1995. (View Abstract)
  • Narod, S., Ford, D., Devilee, P., Barkardottir, R.B., Eyfjörd, J., Lenoir, G., Serova, O., Easton, D., and Goldgar, D. Genetic heterogeneity of breast-ovarian cancer revisited. Am. J. Hum. Genet. 57: 957-958, 1995.

1997

  • Devilee, P., Hermans, J., Eyfjörd, J., Børessen, A.-L., Lidereau, R., Sobol, H., Borg, Å., Cleton-Jansen, A.-M., Olàh, E., Cohen, B.B., Scherneck, S., Hamann, U., Peterlin, B., Caligo, M., Bignon, Y.-J., Maugard, C., and The Breast Cancer Somatic Genetics Consortium. Loss of heterozygosity at 7q31 in breast cancer: results from an international collaborative study group. Genes Chrom. Cancer 18: 193-199, 1997. (View Abstract)
  • The Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505-1510, 1997. (View Abstract)

1998

  • Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjörd J, Lynch H, Ponder BA, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y-J, Borg Å, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, and the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 62: 676-689, 1998. (View Abstract)
  • Phelan CM, Borg Å, Cuny M, Crichton DN, Baldersson T, Andersen TI, Caligo MA, Lidereau R, Lindblom A, Seitz S, Kelsell D, Hamann U, Rio P, Thorlacius S, Papp J, Olah E, Ponder B, Bignon Y-J, Scherneck S, Barkardottir R, Borresen-Dale A-L, Eyfjörd J, Theillet C, Thompson AM, Devilee P, and Larsson C. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res. 58: 1004-1012, 1998. (View Abstract)
  • Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, and Goldgar D. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am. J. Hum. Genet. 62: 1381-1388, 1998. (View Abstract)
  • Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90: 1138-1145, 1998. (View Abstract)

1999

  • Launonen V, Laake K, Huusko P, Niederacher D, Beckmann MW, Barkardottir RB, Geirsdottir EK, Gudmundsson J, Rio P, Bignon YJ, Seitz S, Scherneck S, Bieche I, Champeme MH, Birnbaum D, White G, Varley J, Sztan M, Olah E, Osorio A, Benitez J, Spurr N, Velikonja N, Peterlin B, Borg A, Cleton-Jansen AM, Devilee P, Bloigu R, Lidereau R, Borresen-Dale AL, and Winqvist R. European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Br. J. Cancer 80:879-882, 1999. (View Abstract)
  • Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 Mutation Carriers.  J. Natl. Cancer Inst. 91:1310-1316, 1999. (View Abstract)
  • Shugart YY, Cour C, Renard H, Lenoir G, Goldgar D, Teare D, Easton D, Rahman N, Gusterton R, Seal S, Barfoot R, Stratton M, Mangion J, Peelen T, van den Ouweland A, Meijers H, Devilee P, Eccles D, Lynch H, Weber B, Stoppa-Lyonnet D, Bignon YJ, and Chang-Claude J. Linkage analysis of 56 multiplex families excludes the Cowden disease gene PTEN as a major contributor to familial breast cancer. J. Med. Genet. 36: 720-721, 1999 (Letter, no abstract available).

2000

  • Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, and Stratton MR. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin. Cancer Res. 6: 782-789, 2000. (View Abstract)
  • Rahman N, Teare MD, Seal S, Renard H, Mangion J, Cour C, Thompson D, Shugart Y, Eccles D, Devilee P, Meijers H, Nathanson KL, Neuhausen SL, Weber B, Chang-Claude J, Easton DF, Goldgar D, and Stratton MR. Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. Oncogene 19: 4170-4173, 2000. (View Abstract)

2001

  • Thompson D, Easton D, and the Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet. 68: 410-419, 2001. (View Abstract)

2002

  • Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, Renard H, KConFab Consortium, Mann G, Hopper JL, Buys SS, Andrulis IL, Senie R, Daly MB, West D, Ostrander EA, Offit K, Peretz T, Osorio A, Benitez J, Nathanson KL, Sinilnikova OM, Olah E, Bignon YJ, Ruiz P, Badzioch MD, Vasen HF, Futreal AP, Phelan CM, Narod SA, Lynch HT, Ponder BA, Eeles RA, Meijers-Heijboer H, Stoppa-Lyonnet D, Couch FJ, Eccles DM, Evans DG, Chang-Claude J, Lenoir G, Weber BL, Devilee P, Easton DF, Goldgar DE, and Stratton MR. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc. Natl. Acad. Sci. USA 99:827-831, 2002. (View Abstract)
  • Thompson D, Easton D, and the Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol. Biomarkers Prev. 11: 329-336, 2002. (View Abstract)
  • Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF, and the Breast Cancer Linkage Consortium. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20: 2310-2318, 2002. (View Abstract)

Collaborative spin-off publications

1994

  • Stratton, M., Ford, D., Neuhausen, S., Seal, S., Wooster, R., Friedman, L., King, M.-C., Egilsson, V., Devilee, P., McManus, R., Daly, P., Smyth, E., Ponder, B., Peto, J., Cannon-Albright, L., Easton, D., and Goldgar, D. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nature Genet. 7: 103-107, 1994. (View Abstract)
  • Wooster, R., Neuhausen, S., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., Fields, P., Marshall, G., Narod, S., Lenoir, G., Lynch, H., Feunteun, J., Devilee, P., Cornelisse, C., Menko, F., Daly, P., Ormiston, W., McManus, R., Pye, C., Lewis, C., Cannon-Albright, L., Peto, J., Ponder, B., Skolnick, M., Easton, D., Goldgar, D., and Stratton, M. Localization of a breast cancer susceptibility gene BRCA2 to chromosome 13q12. Science 265: 2088-2090, 1994. (View Abstract)

1995

  • Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., Barfoot, R., Hamoudi, R., Patel, S., Rice, C., Biggs, P., Hashim, Y., Smith, A., Connor, F., Arason, A., Gudmundsson, J., Ficenec, D., Kelsell, D., Ford, D., Tonin, P., Bishop, D.T., Spurr, N.K., Ponder, B.A.J., Eeles, R., Peto, J., Devilee, P., Cornelisse, C.J., Lynch, H., Narod, S., Lenoir, G., Egilsson, V., Barkardottir, R.B., Easton, D.F., Bentley, D.R., Futreal, P.A., Ashworth, A., and Stratton, M.R. Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995. (View Abstract)

1996

  • Neuhausen, S.L., Mazoyer, S., Friedman, L., Stratton, M., Offit, K., Caligo, A., Tomlinson, G., Cannon-Albright, L., Bishop, T., Kelsell, D., Solomon, E., Weber, B., Couch, F., Struewing, J., Tonin, P., Durocher, F., Narod, S., Skolnick, M.H., Lenoir, G., Serova, O., Ponder, B.A.J., Stoppa-Lyonnet, D., Easton, D., King, M.-C., and Goldgar, D.E. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am. J. Hum. Genet. 58: 271-280, 1996. (View Abstract)
  • Phelan, C.M., Rebbeck, T.R., Weber, B.L., Devilee, P., Ruttledge, M.H., Lynch, H.T., Lenoir, G.M., Stratton, M.R., Easton, D.F., Ponder, B.A.J., Cannon-Albright, L., Larsson, C., Goldgar, D.E., and Narod, S.A. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet. 12: 309-311, 1996. (View Abstract)

Back to the BCLC Homepage